Juan Fueyo, MD, Professor in the Department of Neuro-Oncology at MD Anderson Cancer Center, gave an oral presentation of clinical results showing that DNX-2401 therapy for high grade malignant glioma leads to a reduction in the expression of TIM3, a key marker of T-cell exhaustion and negative regulator of antitumor immunity. These results are consistent with DNX-2401 triggering an anti-tumor immune response in patients.
Additional results were presented by scientists and physicians from Erasmus MC (Rotterdam, Netherlands) and Clínica Universidad de Navarra (Pamplona, Spain), demonstrating that DNX-2401 treatment promotes a microenvironment that is detrimental to tumors and is efficacious in a model of pediatric central nervous system tumors, a devastating disease in children.
"We are excited that this important research was selected for presentation at SNO, the premier conference for neuro-oncology," said Frank Tufaro, PhD, CEO of DNAtrix. "These results are encouraging and provide further support for the use of our lead product, DNX-2401, in combination with immunotherapeutic agents such as checkpoint inhibitors, a clinical study which is in progress."
Details of the presentations on DNX-2401 (also known as Delta-24-RGD) are as follows:
Immunomarkers in the DNX-2401 (Delta-24-RGD) oncolytic virus Phase I clinical trial
Abstract Number: ATIM-08
Presenter: Juan Fueyo, MD, MD Anderson Cancer Center, Houston, TX
Date: Sunday, November 19, 2017
Oncolytic viral therapy with Delta-24-RGD induces a tumor-detrimental environment via phenotypic shift of macrophages
Abstract Number: TMIC-03
Presenter: Wouter van den Bossche, Erasmus Medical Center, Rotterdam, Netherlands
Date: Friday, November 17, 2017
The oncolytic adenovirus Delta-24-RGD mediates an efficient antitumor response in vivo in supratentorial primitive neuroectodermal tumors
Abstract Number: PDTM-12
Presenter: Marc Garcia-Moure, PhD, Clínica Universidad de Navarra, Pamplona, Spain
For more information about ongoing DNAtrix clinical studies, visit the ClinicalTrials.gov website: NCT02798406 (DNX-2401 + KEYTRUDA for recurrent glioblastoma) and NCT03178032 (DNX-2401 for newly diagnosed pediatric diffuse intrinsic pontine glioma).
DNX-2401 is an investigational oncolytic immunotherapy designed to treat cancer. DNX-2401 sets off a chain reaction of tumor cell killing by selectively replicating within glioblastoma cells (but not normal cells), causing tumor destruction and further spread of the oncolytic virus to adjacent tumor cells. This process then triggers an immune response directed against the tumor. DNX-2401 has been well tolerated in patients with recurrent glioblastoma and survival has been prolonged compared to other therapies.
DNAtrix is a privately held, clinical stage, biotechnology company developing oncolytic virus immunotherapies for cancer. DNAtrix's lead product, DNX-2401, is a conditionally replicative oncolytic adenovirus being evaluated in clinical trials for recurrent glioblastoma, a brain cancer for which there is neither a cure nor adequate treatment. The company is backed by Morningside Ventures and Mercury Fund, and has been awarded a grant from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit the company website at www.dnatrix.com.
Imran Alibhai, PhD
SVP Business Development
To read more Press Release articles, click here.